Results 121 to 130 of about 102,788 (290)

Variations in Innate Immune Cell Subtypes Correlate with Epigenetic Clocks, Inflammaging and Health Outcomes

Advanced Science, EarlyView.
This study uses a high‐resolution DNA methylation reference panel for 19 immune cell‐types, as well as transcriptomic, metabolomic, and large population cohort data to show that age‐related epigenetic heterogeneity within monocytes correlates with inflammaging, biological age, and all‐causemortality, and does so more strongly than existing monocyte ...
Xiaolong Guo, Josephine A. Robertson, Andrea Aparicio, Kirsten Seale, Qingwen Chen, Anne Richmond, Zhaozhen Du, Mahnoor Sulaiman, Shijie C Zheng, Esteban Ballestar, Charlotte AM Cecil, Bastiaan T Heijmans, Steve Horvath, Varun B. Dwaraka, Jessica Lasky‐Su, Ryan Smith, Riccardo E. Marioni, Andrew E Teschendorff   +17 more
wiley   +1 more source

De novo chronic lymphocytic leukemia/prolymphocytic leukemia or B-cell prolymphocytic leukemia? The importance of integrating clinico-morphological and immunophenotypic findings in distinguishing chronic lymphoproliferative diseases with circulating phase

Autopsy and Case Reports, 2021
B-cell prolymphocytic leukemia (B-PLL) is an extremely rare disease, accounting for approximately 1% of the lymphocytic leukemias. B-PLL generally occurs in older people.
Zachariah Chowdhury, Yookarin Khonglah, Susmita Sarma, Pranjal Kalita   +3 more
doaj  

Src Reduces Neutrophil Extracellular Traps Generation and Resolves Acute Organ Damage

Advanced Science, EarlyView.
Src reduces neutrophil extracellular traps (NETs) generation and resolves acute organ damage. Src directly activates RAF1 by regulating phosphorylation at the Ser 621 site and mediates the RAF/MEK/ERK pathway, thereby affecting the intracellular ROS production. Alternatively, Src activates the RAF1/MEK/ERK pathway by mediating PKC phosphorylation.
Guotao Lu, Fei Han, Yaodong Wang, Chenchen Yuan, Qingtian Zhu, Tianqi Xia, Lin Chen, Xiaowu Dong, Yanbing Ding, Weiming Xiao, Yuyan Zhang, Jiajia Pan, Hongwei Xu, Weiwei Chen, Bo Tu, Wei Li, Fei Wang, Weijuan Gong, Lianghao Hu   +18 more
wiley   +1 more source

NamiRNA‐Enhancer Network: The Changing Era Challenge and Chance of miRNA

Advanced Science, EarlyView.
MiRNAs (miRNAs) regulate diverse biological processes across species. Unlike canonical miRNA‐mediated gene repression, Nuclear Activating miRNAs (NamiRNAs) can efficiently upregulate gene expression by targeting enhancers. This review systematically summarizes recent advances in NamiRNA research, elucidates the theory of NamiRNA‐Enhancer‐mediated Gene ...
Lu Chen, Ying Liang, Hongyan Wei, Mengxing Liu, Jin Wu, Wei Li, Wenxuan Li, Yuxiao Jin, Yinshan Li, Wei Zhao, Min Xiao, Kaicheng Zhou, Shuai Yang, Wenqiang Yu   +13 more
wiley   +1 more source

Unexpected chronic lymphocytic leukemia B cell activation by bisphosphonates

Cancer Immunology, Immunotherapy
AbstractChronic lymphocytic leukemia (CLL) is a disease of the elderly, often presenting comorbidities like osteoporosis and requiring, in a relevant proportion of cases, treatment with bisphosphonates (BPs). This class of drugs was shown in preclinical investigations to also possess anticancer properties. We started an in vitro study of the effects of
Mazzarello, Andrea N., Gugiatti, Elena, Cossu, Vanessa, Bertola, Nadia, Bagnara, Davide, Carta, Sonia, Ravera, Silvia, Salvetti, Chiara, Ibatici, Adalberto, Ghiotto, Fabio, Colombo, Monica, Cutrona, Giovanna, Marini, Cecilia, Sambuceti, Gianmario, Fais, Franco, Bruno, Silvia   +15 more
openaire   +4 more sources

Protein Spatial Structure Meets Artificial Intelligence: Revolutionizing Drug Synergy–Antagonism in Precision Medicine

Advanced Science, EarlyView.
This review comprehensively examines the applications of protein three‐dimensional structures and artificial intelligence in investigating drug synergistic and antagonistic effects. The research findings provide compelling evidence for the precision treatment of cancer and metabolic diseases, thereby promoting the development of personalized medicine ...
Anqi Lin, Chang Che, Aimin Jiang, Chang Qi, Antonino Glaviano, Zhijie Zhao, Zhirou Zhang, Zaoqu Liu, Ziyao Zhou, Quan Cheng, Shuofeng Yuan, Peng Luo   +11 more
wiley   +1 more source

Nature‐Inspired Nanostructures from Multiple‐Species Biomembranes: Rational Engineering and Therapeutic Applications in Tumor‐Targeted Nanomedicine

Advanced Science, EarlyView.
Naturally derived biomembrane nanostructures by mimicking evolutionarily optimized biological architectures could effectively suppress tumor growth and have emerged as a compelling strategy in translational biomedicine. This review provides a systematic overview of rational design and underlying antitumor therapeutic mechanisms of mammalian cells ...
Xiaodan Wei, Chi Wang, Xiangyan Chen, Yuanyuan Zhu, Mei Yang, Ningxi Li, Honglin Huang, Guangjian Zhang, Mingzhen Zhang, Yiyao Liu, Rui Gao   +10 more
wiley   +1 more source

Diagnosis and treatment of chronic lymphocytic leukemia: recommendations from the Brazilian Group of Chronic Lymphocytic Leukemia

Revista Brasileira de Hematologia e Hemoterapia
Chronic lymphocytic leukemia is characterized by clonal proliferation and progressive accumulation of B-cell lymphocytes that typically express CD19+, CD5+ and CD23+.
Celso Arrais Rodrigues, Matheus Vescovi Gonçalves, Maura Rosane Valério Ikoma, Irene Lorand-Metze, André Domingues Pereira, Danielle Leão Cordeiro de Farias, Maria de Lourdes Lopes Ferrari Chauffaille, Rony Schaffel, Eduardo Flávio Oliveira Ribeiro, Talita Silveira da Rocha, Valeria Buccheri, Yuri Vasconcelos, Vera Lúcia de Piratininga Figueiredo, Carlos Sérgio Chiattone, Mihoko Yamamoto   +14 more
doaj   +1 more source

CXCL13 Expression Promotes CAR T Cell Antitumor Activity and Potentiates Response to PD‐1 Blockade

Advanced Science, EarlyView.
This study demonstrates that engineering CAR T cells to express CXCL13 enhances their antitumor efficacy and significantly improves responsiveness to PD‐1 immune checkpoint blockade. CXCL13 promotes T cell persistence, and resistance to early exhaustion via the AKT‐mTOR pathway.
Yang Zhou, Wenli Zhao, Yihan Zhu, Hongyan Liu, Yicheng Sun, Zhengrong Gong, Xuanyi Li, Ziying Liu, Kang Wen, Yicheng Wang, Jie Ren, Ruipei Xiao, Ling Jiang, Yanfeng Hu, Enguang Bi, Xiaoyong Zhang   +15 more
wiley   +1 more source

Bispecific Nanosystems Enable Multieffector Immune Cell Retargeting for Hematologic Malignancy Therapy

Advanced Science, EarlyView.
B‐cell lymphomas are aggressive malignancies with limited treatment options. A bispecific nanosystem (biHSNPs) is developed, leveraging silica nanoplatforms to conjugate antibodies targeting immune effector cells and B‐cell antigens. biHSNPs form artificial immunological synapses, activating cytotoxic responses and suppressing tumor proliferation. This
Yefeng Shen, Xin Li, Jingnan Wu, Yuru Ma, Sven Borchmann, Zhenguo Cheng, Yaohe Wang, Yongliang Zhao, Jian Song, Boyu Luo, Xiuyun Liu, Yue Teng, Zhiyuan Shi   +12 more
wiley   +1 more source